Abstracts tagged "gout"

Abstract Number: 1173 • 2013 ACR/ARHP Annual Meeting
A Clinically Significant Interaction Between Furosemide and Allopurinol: Potential Implications for Clinical Practice
Lisa K. Stamp¹, Claudia Knake² and Andrew Bahn², ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Physiology, University of Otago, Dunedin, New Zealand
Background/Purpose: The xanthine oxidase (XO) inhibitor allopurinol is the most commonly used urate lowering therapy in gout. Allopurinol is metabolized to oxypurinol, which is responsible…
Abstract Number: 1914 • 2012 ACR/ARHP Annual Meeting
The Diagnosis and Management of Gout in 2012: Survey of US and Canadian Rheumatologists
John J. Cush¹ and Robert T. Keenan², ¹Baylor Research Institute, Dallas, TX, ²Rheumatology, Duke University, Durham, NC
Background/Purpose: The introduction of novel treatment modalities for gout has escalated interest and education on this topic. Although gout is the most common inflammatory arthropathy…
Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Robert R. Evans¹, Steven P. Weinstein², George D. Yancopoulos³ and Yuhwen Soo⁴, ¹Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…
Abstract Number: 1915 • 2012 ACR/ARHP Annual Meeting
Elevated Serum Homocysteine Levels Were Related Not with Serum Uric Acid Levels but with Decreased Renal Function in Chronic Gouty Patients
Sang Tae Choi¹, Jung-Soo Song¹, Jin Su Kim², Eun-Jin Kang³, Kwang-Hoon Lee⁴ and You-Jung Ha⁵, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Chung-Ang University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Dongguk University Ilsan Hospital, Goyang, South Korea, ⁵Kwandong University college of Medicine, Goyang, South Korea
Background/Purpose: Hyperhomocysteinemia, which is related with cardiovascular diseases and metabolic syndrome, is regarded as one of the important factors in endothelial cell damage processes. It…
Abstract Number: 156 • 2012 ACR/ARHP Annual Meeting
Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Eswar Krishnan¹ and Mihoko Bennett², ¹Medicine, Standford University, Palo Alto, CA, ²Pediatrics, Stanford University, Palo Alto, CA
Background/Purpose: Among women, the prevalence of gouty arthritis (gout) and hyperuricemia (serum urate>6.0 mg/dL) increases steeply after the age 60. This increase has been attributed…
Abstract Number: 1813 • 2012 ACR/ARHP Annual Meeting
Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
Jasvinder A. Singh, Department of Medicine, University of Alabama, Tuscaloosa, AL
Background/Purpose: Gout outcome studies have used administrative and claims databases. It is unknown whether administrative-derived data are accurate for gout-related utilization. The goal of the…
Abstract Number: 157 • 2012 ACR/ARHP Annual Meeting
Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is a major route of clearance of uric acid, a product of purine metabolism. The links between kidney disease, hyperuricemia, and gout…
Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Michael A. Becker¹, Xiangyang Ye², Kasem S. Akhras³, Rima H. Tawk⁴, Sudhir Unni², Jason Young² and Carl V. Asche⁵, ¹Medicine, University of Chicago, Chicago, IL, ²University of Utah College of Pharmacy, Salt Lake City, UT, ³Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ⁴Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, ⁵Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…
Abstract Number: 158 • 2012 ACR/ARHP Annual Meeting
Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study
Puja Khanna¹, Veronica Berrocal², Tonya Hays³, Daniel J. Clauw⁴ and David A. Williams⁵, ¹Division of Rheumatology/Dept. of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ³Survey Research Center, UCLA, Los Angeles, CA, ⁴Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁵Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI
Background/Purpose: Gout is the most treatable arthritis in the Western World and there are effective medications available to treat both acute episodes and chronic gout.…
Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Kim Coley¹, Melissa Saul² and Karen Pater¹, ¹Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…
Abstract Number: 162 • 2012 ACR/ARHP Annual Meeting
Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients
Filipi M. Mello¹, Rafael B. Tomita², Ricardo Fuller³, Marco Antonio G. P. Filho², Thiago B. M. Barros⁴, Leandro L. do Prado², Kristopherson L. Augusto² and Claudia Goldenstein-Schainberg⁵, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Rheumatology Division - University of São Paulo, São Paulo, Brazil, ³Reumatologia, Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Rheumatology Division - University of São Paulo, São Paulo, Brazil
Background/Purpose: Gout patients have a high frequency of metabolic syndrome (MS), a disorder known to be associated with hyperinsulinemia. The latter condition augments proximal tubular…
Abstract Number: 2043 • 2012 ACR/ARHP Annual Meeting
Documentation of Improvement Over 2 Months in Osteoarthritis, Systemic Lupus Erythematosus, Spondyloarthropathy and Gout Similarly to Rheumatoid Arthritis According to Function, Pain, Patient Global Estimate and RAPID3 On a Multidimensional Health Assessment Questionnaire (MDHAQ)
Isabel Castrejón¹, Martin J. Bergman² and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Taylor Hospital, Ridley Park, PA
Background/Purpose: The health assessment questionnaire (HAQ) and multidimensional HAQ (MDHAQ) were developed initially to assess patients with rheumatoid arthritis (RA). The most feasible method to…
Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…
Abstract Number: 163 • 2012 ACR/ARHP Annual Meeting
Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout
Melea Ward¹, Anthony M. Louder², Keith A. Szymanski³ and Leonardo Tamariz⁴, ¹Competitive Health Analytics, Louisville, KY, ²Competitive Health Analytics, Inc., Louisville, KY, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL, ⁴University of Miami, Miami, FL
Background/Purpose: Higher serum uric acid levels in gout patients have been associated with an increased frequency and risk of gout flares and greater subsequent healthcare…
Abstract Number: 2045 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns and Monitoring of Serum Uric Acid Levels in a Large Cohort of Gout Patients in the United States: Is There Room for Improvement?
Yong Chen¹, Kasem S. Akhras², Michael Grabner¹, Rima H. Tawk³ and Ralph Quimbo¹, ¹HealthCore, Inc., Wilmington, DE, ²Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ³Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Currently, there are no guidelines in the United States on monitoring serum uric acid (sUA) levels in gout and gout treatment patterns. However, there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].